Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road

OncoImmunology

Volumn 2, Issue 11, 2013, Pages

  Wang, Liang Chuan S ^a   Riese, Matthew J ^b   Moon, Edmund K ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Chimeric Antigen Receptor; Diacylglycerol kinase; T cell hypofunction; Tumor immunosuppression; Tumor microenvironment

Indexed keywords

ADENOSINE; DIACYLGLYCEROL KINASE; LYMPHOCYTE ANTIGEN RECEPTOR; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHIMERA; EFFECTOR CELL; GENE DELETION; HUMAN; MACROPHAGE; NEUTROPHIL; NONHUMAN; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84892406353     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26492     Document Type: Article

References (10)

1. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117:1204-12; PMID:17476350; http://dx.doi.org/10.1172/JCI31446.
2. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446.
3. Porter D, Levine B, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849.
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi. org/10.1056/NEJMoa1215134.
5. Müller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010; 10:645-56; PMID:20725108; http://dx.doi. org/10.1038/nri2818.
6. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011; 71:5697-706; PMID:21742772; http://dx.doi.org/10.1158/0008-5472.CAN-11-0103.
7. Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010; 18:2006-17; PMID:20842106; http://dx.doi. org/10.1038/mt.2010.185.
8. Iyer S, Wang ZG, Akhtari M, Zhao W, Seth P. Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 2005; 4:261-6; PMID:15846079; http://dx.doi.org/10.4161/cbt.4.3.1566.
9. Riese MJ, Wang L-CS, Moon EK, Joshi RP, Ranganathan A, June CH, Koretzky GA, Albelda SM. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res 2013; 73:3566-77; PMID:23576561; http://dx.doi. org/10.1158/0008-5472.CAN-12-3874.
10. Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, Zhong XP. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 2006; 7:1174-81; PMID:17028587; http://dx.doi.org/10.1038/ni1400.